Rocket Lab has extensive sell-side coverage, but the stock's October 2026 selloff — triggered by the delay of its next-generation Neutron rocket — reset many estimates. The central $100 target here reflects nine recent, attributed price targets reviewed after that announcement: Cantor Fitzgerald (Andres Sheppard) at $122, Stifel at $132, Needham (Ryan Koontz) at $120, Roth Capital (Suji Desilva) at $110, Clear Street (Greg Pendy) at $105, KeyBanc at $100, Citizens (Trevor Walsh) at $90, Raymond James at $80, and Goldman Sachs (Noah Poponak) at $67. Their arithmetic mean is roughly $103, rounded to a clean $100 for this analysis, across a range of $67 to $132.
Larger aggregator sets (about 19 to 21 analysts) report an average target in the low $100s and a mostly "Buy" or "Strong Buy" consensus, with only a handful of Hold ratings and no Sells. The divergence is telling: bulls such as Stifel and Cantor Fitzgerald see limited long-term impact from the Neutron delay, while Goldman and Raymond James take a more cautious view of cash burn and execution risk. Several firms cut targets after the delay — Citizens from $130 to $90, KeyBanc from $135 to $100, Clear Street from $129 to $105, and Goldman from $75 to $67 — even as most kept buy-equivalent ratings.
Rocket Lab Corporation is an aerospace company providing Electron rocket launch services, spacecraft and satellite systems, and on-orbit operations. Shares closed around $53.67 on October 21, 2026, down roughly 65% from a 52-week high of $151.00 and below both the 50-day (near $68) and 200-day (near $81) moving averages. Reaching $100 would require an approximately 86% gain — a very large move that implies a substantial re-rating of a company that is not yet profitable.
The path is not linear. Rocket Lab grew trailing twelve-month revenue to about $769 million, up more than 50% year over year, and reported a record $2.36 billion backlog. Yet it still posts a net loss (roughly $165 million over the trailing twelve months) and trades near a 53 times price-to-sales (P/S) multiple, an elevated valuation for a pre-profit launch business. Much of the next leg hinges on Neutron, a reusable medium-lift rocket meant to carry about 13,000 kilograms versus Electron's roughly 300, and priced near $50–$55 million per launch compared with $8.5–$10 million for Electron.
The fundamental growth story remains intact. Demand for launch capacity is strong, and Rocket Lab's established Electron cadence, global launch sites, and diversified commercial and government customer base provide a foundation. The company has secured major contracts, including U.S. Space Force awards totaling roughly $663 million announced in mid-2026 and a 20-launch Electron agreement with Synspective. Management has guided to $250–$265 million in third-quarter revenue, and the backlog, up more than 100% year over year, signals continued demand. If Neutron achieves a successful first flight and begins generating revenue, analysts who see the medium-lift market as "only getting bigger" could re-rate the shares sharply higher. Notably, ARK Investment Management added to its position after the post-delay selloff.
The principal obstacle is execution. Neutron's first launch was pushed from the fourth quarter of 2026 to 2027 after engineers found air pockets, or voids, in the carbon-composite first-stage tank dome — a defect that forced a manufacturing rebuild. Goldman Sachs specifically cited higher expenses and cash burn, while Citizens warned the delay's most significant impact falls on monetizing launches in fiscal 2027 and 2028. Rocket Lab is not generating positive free cash flow, and management has indicated that milestone is unlikely until 18 to 24 months after Neutron's first successful launch. A near-$8 billion agreement to acquire Iridium Communications also adds integration and financing considerations. Finally, an extended delay or a failed test could compress the premium P/S multiple further, as the valuation currently embeds substantial future growth.
The chart reflects the sharpest drawdown in the stock's recent history. The 52-week range of $37.57 to $151.00 defines the broad structure, with the $151 area acting as the prior all-time high and major resistance far above current levels. A psychological support zone sits near $50, and the 52-week low near $37.57 is the next durable floor below that. Because the stock trades beneath its 50-day and 200-day moving averages, the intermediate trend remains downward, meaning any sustained push toward $100 would first require reclaiming the mid-$60s and then the $80s, where the moving averages currently sit. A high five-year beta near 2.9 underscores how much more volatile the stock is than the broader market.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms can differ, and targets for Rocket Lab are being revised frequently. The next earnings report, expected in early November, will test whether third-quarter revenue lands within the $250–$265 million guidance range and whether the backlog continues to build. Investors should watch Neutron manufacturing and testing milestones, any updated launch-date guidance, progress on the Iridium acquisition, further Space Force or commercial contract awards, and revisions to analyst targets. Rate decisions and broader risk appetite also matter for a high-beta, pre-profit growth stock.
Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like Rocket Lab, such tools can help traders surface opportunities, track existing positions, and spot shifts in trend more efficiently than manual scanning. Traders exploring these signals can use them to complement their own research and stay ahead of evolving market conditions.
Can Rocket Lab reach $100? The central target of $100 — the rounded mean of nine verified analyst price targets — implies a very large move of about 86% from the recent price near $53.67. The bull case rests on rapid revenue growth, a record backlog, strong government demand, and the long-term potential of Neutron. The bear case rests on the Neutron delay, ongoing losses, elevated valuation, and the time required to reach positive free cash flow. The wide $67-to-$132 analyst range captures that uncertainty. Whether the shares approach $100 will likely depend less on the launch business already running well and more on Neutron's execution and the company's path to profitability — factors no price target can guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RKLB has been closely correlated with LUNR. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if RKLB jumps, then LUNR could also see price increases.
| Ticker / NAME | Correlation To RKLB | 1D Price Change % | ||
|---|---|---|---|---|
| RKLB | 100% | +2.69% | ||
| LUNR - RKLB | 78% Closely correlated | +0.67% | ||
| FLY - RKLB | 76% Closely correlated | +4.05% | ||
| PL - RKLB | 68% Closely correlated | +2.52% | ||
| VOYG - RKLB | 64% Loosely correlated | +5.33% | ||
| KTOS - RKLB | 59% Loosely correlated | +1.07% | ||
More | ||||